MedElevator
Войти в исследования BMC psychiatry · 2026
Assessment of oxidative stress markers in multi-episode schizophrenia: a comparative study before and after electroconvulsive therapy and their correlation with clinical improvement.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Man, Tian Qing, Yuan Xue, Liu Dongliang, Shi Qiang, Yang Haidong, Zhang Xiaobin
Аннотация
OBJECTIVE: This study examined oxidative stress (OS) markers in acute relapse schizophrenia, assessed the impact of electroconvulsive therapy (ECT), and explored correlations with clinical improvement.
METHODS: 110 Han Chinese patients and 55 healthy controls were enrolled. All enrolled patients had multi-episode schizophrenia with a mean illness duration of 11.15 ± 9.11 years. Patients received 8-12 bilateral ECT sessions plus antipsychotics. Serum levels of GSH-Px, MnSOD, CuZnSOD, and CAT were measured before and after ECT. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS).
RESULTS: At baseline, schizophrenia patients showed significantly lower serum levels of GSH-Px, MnSOD, and CAT, while the MnSOD/CuZnSOD ratio was decreased, CuZnSOD levels showed a non‑significant trend as compared to healthy controls. GSH-Px levels were negatively correlated with the PANSS positive subscale scores (p = 0.007). Following ECT, all PANSS scores significantly decreased (all p < 0.001). Serum levels of GSH-Px, TSOD, CuZnSOD, and CAT increased significantly, while MnSOD levels and the MnSOD/CuZnSOD ratio significantly decreased (all p < 0.01). In responders, changes to OS markers were significant (all p < 0.01). Increases in GSH-Px levels were positively correlated to reductions in the PANSS total score (Bonferroni corrected p = 0.024) and general subscale scores (Bonferroni corrected p = 0.008). Multivariate logistic regression analysis identified the baseline GSH-Px level as an independent potential indicator of clinical improvement (p = 0.001).
CONCLUSION: Acute relapse schizophrenia shows significant redox imbalance. ECT in combination with antipsychotics modulates antioxidant enzymes, and GSH-Px dynamics correlate with symptom improvement, suggesting its potential as a predictive and monitoring biomarker for ECT outcomes.
CLINICAL TRIAL: Not applicable.
METHODS: 110 Han Chinese patients and 55 healthy controls were enrolled. All enrolled patients had multi-episode schizophrenia with a mean illness duration of 11.15 ± 9.11 years. Patients received 8-12 bilateral ECT sessions plus antipsychotics. Serum levels of GSH-Px, MnSOD, CuZnSOD, and CAT were measured before and after ECT. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS).
RESULTS: At baseline, schizophrenia patients showed significantly lower serum levels of GSH-Px, MnSOD, and CAT, while the MnSOD/CuZnSOD ratio was decreased, CuZnSOD levels showed a non‑significant trend as compared to healthy controls. GSH-Px levels were negatively correlated with the PANSS positive subscale scores (p = 0.007). Following ECT, all PANSS scores significantly decreased (all p < 0.001). Serum levels of GSH-Px, TSOD, CuZnSOD, and CAT increased significantly, while MnSOD levels and the MnSOD/CuZnSOD ratio significantly decreased (all p < 0.01). In responders, changes to OS markers were significant (all p < 0.01). Increases in GSH-Px levels were positively correlated to reductions in the PANSS total score (Bonferroni corrected p = 0.024) and general subscale scores (Bonferroni corrected p = 0.008). Multivariate logistic regression analysis identified the baseline GSH-Px level as an independent potential indicator of clinical improvement (p = 0.001).
CONCLUSION: Acute relapse schizophrenia shows significant redox imbalance. ECT in combination with antipsychotics modulates antioxidant enzymes, and GSH-Px dynamics correlate with symptom improvement, suggesting its potential as a predictive and monitoring biomarker for ECT outcomes.
CLINICAL TRIAL: Not applicable.